Supplemental table 1: Detailed Search Strategy:

Ovid

Database(s): Embase 1988 to 2014 Week 36, Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) 1946 to Present, EBM Reviews - Cochrane Central Register of Controlled Trials August 2014, EBM Reviews - Cochrane Database of Systematic Reviews 2005 to July 2014
Search Strategy:

#	Searches	Results
1	exp Hepatitis B/dt	26394
2	("hepatitis B" or "serum hepatitis" or "hippie hepatitis" or "injection hepatitis" or "hepatitis type B").mp.	178415
3	1 or 2	178415
4	exp Antiviral Agents/	915473
5	exp antivirus agent/	611278
6	("1-Deoxynojirimycin" or absouline or "abt 333" or "abt 450" or Acetylcysteine or aciclovir or "acyclouridine derivative" or Acyclovir or "adenine xyloside" or "adenosine dialdehyde" or afovirsen or "al 721" or alamifovir or alisporivir or "aln rsv 01" or "alvircept sudotox" or amantadine or amenamevir or amidapsone or amitivir or "ammonium trichloro dioxyethylene o o tellurate" or amsacrine or "ana 975" or "anti viral agent" or AntiRetroviral* or "Anti-Retroviral*" or antiretrovirus or antiviral* or "anti-viral*" or Aphidicolin or arasangivamycin or arbidol or arildone or astodrimer or asunaprevir or avarol or avarone or avridine or "azd 7295" or balapiravir or bavituximab or "behenyl alcohol" or benzimidavir or besifovir or boceprevir or bonaphthone or "Brefeldin A" or brincidofovir or Bromodeoxyuridine or bropirimine or buciclovir or carbocyclic or carbodine or carrageenan or cidofovir or ciluprevir or clevudine or "cpg 10101" or crofelemer or cyclaradine or "cyclosporin A" or cytarabine or daclatasvir or damavaricin or danoprevir or dasabuvir or deitiphorin or deleobuvir or denotivir or deoxyaristeromycin or Deoxyglucose or deoxypenciclovir or deoxyribavirin or desciclovir or detiviciclovir or "didemnin A" or "didemnin B" or Dideoxyadenosine or Dideoxynucleoside* or disoxaril or "distamycin 5" or "distamycin A" or Ditiocarb or droxinavir or edoxudine or elbasvir or "enisamium iodide" or enviroxime or epetirimod or eudistomin or exbivirumab or faldaprevir or famciclovir or favipiravir or felvizumab or fiacitabine or fialuridine or filibuvir or Filipin or florenal or "flucytosine arabinoside" or fomivirsen or foravirumab or fosarilate or foscarnet or fosdevirine or fucoidin or "gamma venin" or ganciclovir or "gene expression modulator" or grazoprevir or "gs 9256" or "guanine 7 oxide" or hypericin or "hypoxanthine arabinoside" or idoxuridine or "idoxuridine derivative" or "idx 184" or imexon or imiquimod or "Inosine Pranobex" or iododeoxycytidine or ipilimumab or isatoribine or "isis 13312" or "isis 14803" or laninamivir or larifan or ledipasvir or letermovir or levovirin or lexithromycin or libivirumab or litomeglovir or lomibuvir or mericitabine or merimepodib or Methisazone or methisoprinol or methylcytidine or metisazone or miravirsen or moroxydine or motavizumab or "mycophenolic acid" or "Myxovirus resistance protein" or "n bromoacetyldistamycin A" or narlaprevir or neceprevir or "neominophagen C" or nesbuvir or netivudine or netropsin or nivocasan or omaciclovir or ombitasvir or oseltamivir or palivizumab or penciclovir or "penciclovir triphosphate" or peramivir or "phosphonoacetic acid" or "Phosphonoacetic Acid" or pirazofurin or pirodavir or pleconaril or pocapavir or "pokeweed antivirus protein" or "Poly A-U" or "Poly I-C" or pritelivir or pseudohypericin or "pyran copolymer" or "Pyran Copolymer" or radavirsen or rafivirumab or "recombinant intercellular adhesion molecule 1" or regavirumab or resiquimod or ribavirin or "ribavirin derivative" or rifabutin or rimantadine or rintatolimod or riodoxol or rociclovir or rupintrivir or samatasvir or sangivamycin or "sangivamycin derivative" or "scopadulcic acid B" or setrobuvir or sevirumab or simeprevir or sofosbuvir or sorivudine or sovaprevir or streptovaricin or Streptovaricin or streptovirudin or suramin or suvizumab or synadenol or synguanol or taribavirin or tebrofen or tecovirimat or tegobuvir or telaprevir or telbivudine or "Tenuazonic Acid" or "thiarubrine A" or "thiophene A" or "thymine arabinoside" or tilorone or Tilorone or "tilorone derivative" or tiviciclovir or tomeglovir or torcitabine or trifluridine or tromantadine or tunicamycin or tuvirumab or umifenovir or "uracil arabinoside" or valaciclovir or valganciclovir or valomaciclovir or valopicitabine or valtorcitabine or vaniprevir or vapendavir or	747307

	vedroprevir or vidarabine or Vidarabine or viracine or "viral inhibitor*" or virantmycin or virostatic* or viroxime or virucidal* or virucide* or "virus repressor*" or virustatic* or xanthogenate or "xenazoic acid" or zanamivir or Zanamivir or zinviroxime).mp.	
7	4 or 5 or 6	1208899
8	exp Interferons/	453504
9	exp interferon/	453504
10	("cl 884" or cl884 or ifn or interferon* or interferone* or interferonogen* or interferron* or "interleukin 28A" or "interleukin 29" or "interleukin 6" or leif or peginterferon* or peginterferone* or peginterferonogen* or peginterferron*).mp.	628658
11	8 or 9 or 10	628758
12	exp Pregnancy/	1080989
13	(pregnan* or gestation* or "child bearing" or childbearing).mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, kf, px, rx, ui, tx, ct]	1448492
14	12 or 13	1463788
15	3 and (7 or 11) and 14	1340
16	exp evidence based medicine/	721205
17	exp meta analysis/	134011
18	exp Meta-Analysis as Topic/	29510
19	exp "systematic review"/	79207
20	exp Guideline/ or exp Practice Guideline/	344377
21	exp controlled study/	4512490
22	exp Randomized Controlled Trial/	723249
23	exp triple blind procedure/	68
24	exp Double-Blind Method/	342895
25	exp Single-Blind Method/	51259
26	exp latin square design/	276
27	exp Placebos/	267995
28	exp Placebo Effect/	7231
29	exp comparative study/	2459742
30	exp Cross-Sectional Studies/	307288
31	exp Cross-Over Studies/	101407
32	exp Cohort Studies/	1680397
33	exp longitudinal study/	1065024
34	exp retrospective study/	864314
35	exp prospective study/	701082
36	exp population research/	68087
37	exp observational study/	65081
38	exp clinical trial/	1728711
39	clinical study/	53598
40	exp Evaluation Studies/	208013
41	exp Evaluation Studies as Topic/	1130031
42	exp Twin Study/	31182
43	exp quantitative study/	5818
44	exp validation studies/	113515
45	exp experimental study/	14612

46	exp quasi experimental study/	2028
47	exp field study/	1531
48	in vivo study/	189705
49	exp panel study/	373
50	exp Pilot Projects/	171018
51	exp pilot study/	171018
52	exp prevention study/	2120
53	exp replication study/	949
54	exp theoretical study/	1368248
55	exp Feasibility Studies/	99507
56	exp Models, Theoretical/	1387826
57	exp trend study/	11365
58	exp correlational study/	11312
59	exp case-control studies/	784804
60	exp confidence interval/	122062
61	exp regression analysis/	570654
62	exp proportional hazards model/	94889
63	exp multivariate analysis/	343014
64	"limit follow up studies to medline only. embase maps to follow up".ti.	0
65	exp follow up studies/	1343640
66	exp case study/	1738225
67	"limit case study above to embase only. medline maps to case report".ti.	0
68	odds ratio/	383358
69	"limit odds ratio above to embase. medline maps to risk".ti.	0
70	((evidence adj based) or (meta adj analys*) or (systematic* adj3 review*) or guideline* or (doubl* adj blind*) or (doubl* adj mask*) or (singl* adj blind*) or (singl* adj mask*) or (tripl* adj blind*) or (tripl* adj mask*) or (trebl* adj blind*) or (trebl* adj mask*) or "latin square" or placebo or random* or control* or multivariate or "comparative study" or "comparative survey" or "comparative analysis" or compar* or (intervention* adj2 study) or (intervention* adj2 trial) or "cross-sectional study" or "cross-sectional analys*" or "cross-sectional survey*" or "cross-sectional design*" or "prevalence study" or "prevalence analys*" or "prevalence survey*" or "disease frequency study" or "disease frequency analys*" or "disease frequency survey*" or crossover or "cross-over" or cohort* or "longitudinal study" or "longitudinal survey" or "longitudinal analysis" or longitudinal* or "retrospective study" or "retrospective survey" or "retrospective analysis" or retrospectiv* or "prospective study" or "prospective survey" or "prospective analysis" or prospectiv* or "population study" or "population survey" or "population analysis" or "concurrent study" or "concurrent survey" or "concurrent analysis" or "incidence study" or "incidence survey" or "incidence analysis" or "follow-up study" or "follow-up survey" or "follow-up analysis" or "observational study" or "observational survey" or "observational analysis" or "case study" or "case series" or "clinical series" or "case studies" or "clinical study" or "clinical trial" or "evaluation study" or "evaluation survey" or "evaluation analysis" or "twin study" or "twin survey" or "twin analysis" or "quantitative study" or "quantitative analys*" or "validation study" or "validation survey" or "validation analysis" or "experimental study" or "experimental analysis " or "quasi experimental study" or "quasi experimental analysis" or "quasiexperimental study" or "quasiexperimental analysis" or "field study" or "field survey" or "field analysis" or "in vivo study" or "in vivo analysis" or "panel study" or "panel survey" or "panel analysis" or "prevention study" or "prevention survey" or "prevention analysis" or "replication study" or "replication analysis " or "theoretical study" or "theoretical analysis " or "feasibility study" or "feasibility analysis " or "trend study" or "trend survey" or "trend analysis" or (correlation* adj2 study) or (correlation* adj2 analys*) or "case control study" or "case base study" or	22128887

	"case referrent study" or "case referent study" or "case compeer study" or "case comparison study" or study or trial or pilot or "odds ratio" or "confidence interval" or "regression analysis" or "hazards model" or "change analysis").mp.	
71	from 65 keep 793339-1301733	508395
72	from 66 keep 1-25622	25622
73	from 68 keep 1-318765	318765
74	or/16-63	12606394
75	or/70-74	23255184
76	15 and 75	934
77	from 15 keep 962-1300	339
78	limit 77 to (clinical trial, all or clinical trial, phase i or clinical trial, phase ii or clinical trial, phase iii or clinical trial, phase iv or clinical trial or comparative study or controlled clinical trial or evaluation studies or guideline or meta analysis or multicenter study or observational study or practice guideline or pragmatic clinical trial or randomized controlled trial or systematic reviews or twin study or validation studies) [Limit not valid in Embase,CCTR,CDSR; records were retained]	83
79	76 or 78	934
80	limit 79 to (book or book series or editorial or erratum or letter or note or addresses or autobiography or bibliography or biography or comment or dictionary or directory or interactive tutorial or interview or lectures or legal cases or legislation or news or newspaper article or overall or patient education handout or periodical index or portraits or published erratum or video-audio media or webcasts) [Limit not valid in Embase,Ovid MEDLINE(R),Ovid MEDLINE(R) In-Process,CCTR,CDSR; records were retained]	41
81	79 not 80	893
82	from 15 keep 1301-1340	40
83	81 or 82	916
84	83 not (exp animals/ not exp humans/)	885
85	from 83 keep 896-916	21
86	84 or 85	906
87	remove duplicates from 86	735

Scopus

1 TITLE-ABS-KEY("hepatitis B" or "serum hepatitis" or "hippie hepatitis" or "injection hepatitis" or "hepatitis type B")

2 TITLE-ABS-KEY("1-Deoxynojirimycin" OR absouline OR "abt 333" OR "abt 450" OR Acetylcysteine OR aciclovir OR "acyclouridine derivative" OR Acyclovir OR "adenine xyloside" OR "adenosine dialdehyde" OR afovirsen OR "al 721" OR alamifovir OR alisporivir OR "aln rsv 01" OR "alvircept sudotox" OR amantadine OR amenamevir OR amidapsone OR amitivir OR "ammonium trichloro dioxyethylene o o tellurate" OR amsacrine OR "ana 975" OR "anti viral agent" OR AntiRetroviral* OR "Anti-Retroviral*" OR antiretrovirus OR antiviral* OR "anti-viral*" OR Aphidicolin OR arasangivamycin OR arbidol OR arildone OR astodrimer OR asunaprevir OR avarol OR avarone OR avridine OR "azd 7295" OR balapiravir OR bavituximab OR "behenyl alcohol" OR benzimidavir OR besifovir OR boceprevir OR bonaphthone OR "Brefeldin A" OR brincidofovir OR Bromodeoxyuridine OR bropirimine OR buciclovir OR carbocyclic OR carbodine OR carrageenan OR cidofovir OR ciluprevir OR clevudine OR "cpg 10101" OR crofelemer OR cyclaradine OR "cyclosporin A" OR cytarabine OR daclatasvir OR damavaricin OR danoprevir OR dasabuvir OR deitiphorin OR deleobuvir OR denotivir OR deoxyaristeromycin OR Deoxyglucose OR deoxypenciclovir OR deoxyribavirin OR desciclovir OR detiviciclovir OR "didemnin A" OR "didemnin B" OR Dideoxyadenosine OR Dideoxynucleoside* OR disoxaril OR "distamycin 5" OR "distamycin A" OR Ditiocarb OR droxinavir OR edoxudine OR elbasvir OR "enisamium iodide" OR enviroxime OR epetirimod OR eudistomin OR exbivirumab OR faldaprevir OR famciclovir OR favipiravir OR felvizumab OR fiacitabine OR fialuridine OR filibuvir OR Filipin OR florenal OR "flucytosine arabinoside" OR fomivirsen OR foravirumab OR fosarilate OR foscarnet OR fosdevirine OR fucoidin OR "gamma venin" OR ganciclovir OR "gene expression modulator" OR grazoprevir OR "gs 9256" OR "guanine 7 oxide" OR hypericin OR "hypoxanthine arabinoside" OR idoxuridine OR "idoxuridine derivative" OR "idx 184" OR imexon OR imiquimod OR "Inosine Pranobex" OR iododeoxycytidine OR ipilimumab OR isatoribine OR "isis 13312" OR "isis 14803" OR laninamivir OR larifan OR ledipasvir OR letermovir OR levovirin OR lexithromycin OR libivirumab OR litomeglovir OR lomibuvir OR mericitabine OR merimepodib OR Methisazone OR methisoprinol OR methylcytidine OR metisazone OR miravirsen OR moroxydine OR motavizumab OR "mycophenolic acid" OR "Myxovirus resistance protein" OR "n bromoacetyldistamycin A" OR narlaprevir OR neceprevir OR "neominophagen C" OR nesbuvir OR netivudine OR netropsin OR nivocasan OR omaciclovir OR ombitasvir OR oseltamivir OR palivizumab OR penciclovir OR "penciclovir triphosphate" OR peramivir OR "phosphonoacetic acid" OR "Phosphonoacetic Acid" OR pirazofurin OR pirodavir OR pleconaril OR pocapavir OR "pokeweed antivirus protein" OR "Poly A-U" OR "Poly I-C" OR pritelivir OR pseudohypericin OR "pyran copolymer" OR "Pyran Copolymer" OR radavirsen OR rafivirumab OR "recombinant intercellular adhesion molecule 1" OR regavirumab OR resiquimod OR ribavirin OR "ribavirin derivative" OR rifabutin OR rimantadine OR rintatolimod OR riodoxol OR rociclovir OR rupintrivir OR samatasvir OR sangivamycin OR "sangivamycin derivative" OR "scopadulcic acid B" OR setrobuvir OR sevirumab OR simeprevir OR sofosbuvir OR sorivudine OR sovaprevir OR streptovaricin OR Streptovaricin OR streptovirudin OR suramin OR suvizumab OR synadenol OR synguanol OR taribavirin OR tebrofen OR tecovirimat OR tegobuvir OR telaprevir OR telbivudine OR "Tenuazonic Acid" OR "thiarubrine A" OR "thiophene A" OR "thymine arabinoside" OR tilorone OR Tilorone OR "tilorone derivative" OR tiviciclovir OR tomeglovir OR torcitabine OR trifluridine OR tromantadine OR tunicamycin OR tuvirumab OR umifenovir OR "uracil arabinoside" OR valaciclovir OR valganciclovir OR valomaciclovir OR valopicitabine OR valtorcitabine OR vaniprevir OR vapendavir OR vedroprevir OR vidarabine OR Vidarabine OR viracine OR "viral inhibitor*" OR virantmycin OR virostatic* OR viroxime OR virucidal* OR virucide* OR "virus

repressor*" OR virustatic* OR xanthogenate OR "xenazoic acid" OR zanamivir OR Zanamivir OR zinviroxime)

3 TITLE-ABS-KEY("cl 884" OR cl884 OR ifn OR interferon* OR interferone* OR interferonogen* OR interferron* OR "interleukin 28A" OR "interleukin 29" OR "interleukin 6" OR leif OR peginterferon* OR peginterferone* OR peginterferonogen* OR peginterferron*)

4 TITLE-ABS-KEY(pregnan* or gestation* or "child bearing" or childbearing)

5 TITLE-ABS-KEY((evidence W/1 based) OR (meta W/1 analys*) OR (systematic* W/3 review*) OR (guideline*) OR (doubl* W/1 blind*) OR (doubl* W/1 mask*) OR (singl* W/1 blind*) OR (singl* W/1 mask*) OR (tripl* W/1 blind*) OR (tripl* W/1 mask*) OR (trebl* W/1 blind*) OR (trebl* W/1 mask*) OR "latin square" OR placebo OR random* OR control* OR multivariate OR "comparative study" OR "comparative survey" OR "comparative analysis" OR compar* OR (intervention* W/2 study) OR (intervention* W/2 trial) OR "cross-sectional study" OR "cross-sectional analys*" OR "cross-sectional survey*" OR "cross-sectional design*" OR "prevalence study" OR "prevalence analys*" OR "prevalence survey*" OR "disease frequency study" OR "disease frequency analys*" OR "disease frequency survey*" OR crossover OR "cross-over" OR cohort* OR "longitudinal study" OR "longitudinal survey" OR "longitudinal analysis" OR longitudinal* OR "retrospective study" OR "retrospective survey" OR "retrospective analysis" OR retrospectiv* OR "prospective study" OR "prospective survey" OR "prospective analysis" OR prospectiv* OR "population study" OR "population survey" OR "population analysis" OR "concurrent study" OR "concurrent survey" OR "concurrent analysis" OR "incidence study" OR "incidence survey" OR "incidence analysis" OR "follow-up study" OR "follow-up survey" OR "follow-up analysis" OR "observational study" OR "observational survey" OR "observational analysis" OR "case study" OR "case series" OR "clinical series" OR "case studies" OR "clinical study" OR "clinical trial" OR "evaluation study" OR "evaluation survey" OR "evaluation analysis" OR "twin study" OR "twin survey" OR "twin analysis" OR "quantitative study" OR "quantitative analys*" OR "validation study" OR "validation survey" OR "validation analysis" OR "experimental study" OR "experimental analysis " Or "quasi experimental study" OR "quasi experimental analysis" OR "quasiexperimental study" OR "quasiexperimental analysis" OR "field study" OR "field survey" OR "field analysis" OR "in vivo study" OR "in vivo analysis" OR "panel study" OR "panel survey" OR "panel analysis" OR "prevention study" OR "prevention survey" OR "prevention analysis" OR "replication study" OR "replication analysis " OR "theoretical study" OR "theoretical analysis " OR "feasibility study" OR "feasibility analysis " OR "trend study" OR "trend survey" OR "trend analysis" OR (correlation* W/2 study) OR (correlation* W/2 analys*) OR "case control study" OR "case base study" OR "case referrent study" OR "case referent study" OR "case compeer study" OR "case comparison study" OR study OR trial OR pilot OR "odds ratio" OR "confidence interval" OR "regression analysis" OR "hazards model" OR "change analysis")

6 1 and 2 and 3 and 4 and 5

7 DOCTYPE(le) OR DOCTYPE(ed) OR DOCTYPE(bk) OR DOCTYPE(er) OR DOCTYPE(no) OR DOCTYPE(sh)

8 6 and not 7

9 PMID(0*) OR PMID(1*) OR PMID(2*) OR PMID(3*) OR PMID(4*) OR PMID(5*) OR PMID(6*) OR PMID(7*) OR PMID(8*) OR PMID(9*)

10 8 and not 9

Supplemental Table 2: Quality of evidence summary:

Intervention	Outcome (Follow up)	No. of participants (Study design)	Quality of the evidence (GRADE)	Relative effect (95% CI)
Infant outcomes:				
Any antiviral vs none	Infant HBsAg seropositivity (6-12 m)	737 (8 RCTs)	⊕⊕⊕◯[1] MODERATE	**RR 0.26** (0.16 to 0.44)
	Infant HBsAg seropositivity (6-12 m)	1190 (9 observational studies)	⊕◯◯◯[1] VERY LOW	**RR 0.21** (0.12 to 0.38)
	Infant HBV DNA positivity (6-12 m)	496 (5 RCTs)	⊕⊕◯◯[13] LOW	**RR 0.31** (0.20 to 0.49)
	Infant HBV DNA positivity (6-12 m)	90 (1 observational studies)	⊕◯◯◯[13] VERY LOW	**RR 0.38** (0.17 to 0.84)
	Congenital malformation rate	1154 (4 observational studies)	⊕◯◯◯[14] VERY LOW	**RR 0.88** (0.21 to 3.62)
	Prematurity rate	812 (5 observational studies)	⊕◯◯◯[4] VERY LOW	**RR 0.73** (0.35 to 1.53)
Lamivudine vs None	Infant HBsAg seropositivity (6-12 m)	444 (5 RCTs) 6-12 months	⊕⊕⊕◯[1] MODERATE	**RR 0.29** (0.15 to 0.56)
	Infant HBsAg seropositivity (6-12 m)	662 (5 observational studies) 6-12 months	⊕◯◯◯[1] VERY LOW	**RR 0.12** (0.03 to 0.45)
	Infant HBV DNA positivity (6-12 m)	322 (3 RCTs) 6-12 months	⊕⊕◯◯[13] LOW	RR 0.34 (0.21 to 0.56)
	Infant HBV DNA positivity (6-12 m)	90 (1 observational study) 6-12 months	⊕◯◯◯[13] VERY LOW	**RR 0.38** (0.17 to 0.84)
	APGAR score	289 (2 observational studies)	⊕◯◯◯[13] VERY LOW	Means differences 0.012 (-0.75 to 0.47)
	Congenital malformation rate	493 (2 observational studies)	⊕◯◯◯ VERY LOW	RR 0.84 (0.09 to 7.4)
	Prematurity rate	514 (3 observational studies)	⊕◯◯◯ VERY LOW	RR 0.76 (0.35 to 1.65)
Telbivudine vs control	Infant HBsAg seropositivity (6-12 m)	293 (4 RCTs) 6-12 months	⊕⊕⊕◯[1] MODERATE	**RR 0.23** (0.10 to 0.52)
	Infant HBsAg seropositivity (6-12 m)	309 (2 observational studies) 6-12 months	⊕◯◯◯[1] VERY LOW	**RR 0.06** (0.01 to 0.49)
	Infant HBV DNA seropositivity (6-12 m)	174 (2 RCTs) 6-12 months	⊕⊕◯◯[13] LOW	RR 0.13 (0.03 to 0.55)
	APGAR score	815 (3 observational studies)	⊕◯◯◯[4] VERY LOW	Means difference -0.009 (-0.048 to 0.03)
	Prematurity rate	220 (1observational studies)	⊕◯◯◯[4] VERY LOW	RR 0.28 (0.01 to 6.76)

Tenofovir vs control	Infant HBsAg seropositivity (6-12 m)	219 (2 observational study)	⊕⊕◯◯ LOW	**RR 0.22** (0.07 to 0.70)
	Congenital malformation rate	122 (2 observational studies)	⊕◯◯◯[4] VERY LOW	RR 1.7 (0.01 to 28.8)
	Prematurity rate	78 (1 observational study)	⊕◯◯◯[4] VERY LOW	RR 1.07 (0.05 to 25.21)
Telbivudine vs lamivudine	Infant HBsAg seropositivity (at birth)	684 (2 observational studies)	⊕◯◯◯[14] VERY LOW	RR 0.98 (0.65 to 1.48)
	Prematurity rate	387 (1 observational study)	⊕◯◯◯[4] VERY LOW	RR 1.89 (0.55 to 7.21)
Tenofovir vs Lamivudine	Infant HBsAg seropositivity (at birth)	87 (1 observational study)	⊕◯◯◯[4] VERY LOW	**RR 2.93** (0.12 to 70.08)
	Congenital malformation rate	111 (1 observational study)	⊕◯◯◯[4] VERY LOW	RR 0.46 (0.04 to 4.9)
	Prematurity rate	111 (1 observational study)	⊕◯◯◯[4] VERY LOW	RR 0.3 (0.03 to 2.84)
Maternal Outcomes:				
Lamivudine vs control	Maternal HBV DNA suppression (at delivery)	185 (1 observational study)	⊕◯◯◯[34] VERY LOW	RR 57.14 (3.54 to 921.41)
	Maternal HBV DNA suppression (4-8 weeks postpartum)	581 (2 observational studies)	⊕◯◯◯[34] VERY LOW	RR 70.93 (8.53 to 589.96)
	ALT normalization (at delivery)	349 (2 observational studies)	⊕◯◯◯[134] VERY LOW	RR 1.3 (0.74 to 2.31)
	Postpartum hemorrhage rate	115 (1 RCT)	⊕⊕◯◯[14] LOW	RR 0.96 (0.7 to 1.31)
	Postpartum hemorrhage rate	514 (3 observational studies)	⊕◯◯◯[14] VERY LOW	RR 0.99 (0.78 to 1.26)
	Cesarean section rate	115 (1 RCT)	⊕⊕◯◯[14] LOW	RR 0.96 (0.71 to 1.3)
	Cesarean section rate	514 (3 observational studies)	⊕◯◯◯[14] VERY LOW	RR 1.08 (0.89 to 1.31)
	Elevated Creatinine kinase rate	185 (1 observational study)	⊕◯◯◯[34] VERY LOW	RR 2.9 (0.12 to 72.03)
Telbivudine vs control	Maternal HBN DNA Suppression (at delivery)	537 (3 observational studies)	⊕◯◯◯[34] VERY LOW	RR 52.83 (10.66 to 261.82)
	Maternal HBN DNA Suppression (4 weeks postpartum)	685 (2 observational studies)	⊕◯◯◯[34] VERY LOW	RR 102.94 (14.4 to 722.83)
	Maternal HBN DNA Suppression (28 weeks postpartum)	88 (1 observational study)	⊕◯◯◯[34] VERY LOW	RR 42 (2.65 to 664.73)
	ALT normalization (at delivery)	161 (2 observational	⊕◯◯◯[3]	RR 1.46

		studies)	VERY LOW	(1.18 to 1.8)
	ALT normalization (4 weeks postpartum)	88 (1 observational study)	⊕◯◯◯[3] VERY LOW	RR 1.59 (1.1 to 2.31)
	ALT normalization (28 weeks postpartum)	88 (1 observational study)	⊕◯◯◯[3] VERY LOW	RR 1.29 (1.04 to 1.62)
	Maternal HBeAg loss (at delivery)	708 (2 observational studies)	⊕◯◯◯[3] VERY LOW	RR 1.67 (1.25 to 2.24)
	Maternal HBeAg loss (4 weeks postpartum)	88 (1 observational study)	⊕◯◯◯[3] VERY LOW	RR 1.64 (1.24 to 2.15)
	Maternal HBeAg loss (28 weeks postpartum)	88 (1 observational study)	⊕◯◯◯[3] VERY LOW	RR 1.67 (1.22 to 2.29)
	Maternal HBeAg seroconversion (at delivery)	708 (2 observational studies)	⊕◯◯◯[34] VERY LOW	RR 2.9 (0.31 to 27.58)
	Maternal HBeAg seroconversion (4 weeks postpartum)	88 (1 observational study)	⊕◯◯◯[34] VERY LOW	RR 3.33 (0.16 to 67.42)
	Maternal HBeAg seroconversion (28 weeks postpartum)	88 (1 observational study)	⊕◯◯◯[34] VERY LOW	RR 11.33 (0.67 to 190.29)
	Cesarean section rate	318 (2 observational studies)	⊕◯◯◯[4] VERY LOW	RR 1.17 (0.94 to 1.45)
	Postpartum hemorrhage	308 (2 observational study)	⊕◯◯◯[4] VERY LOW	RR 0.9 (0.64 to 1.25)
	Elevated Creatinine kinase rate	637 (1 observational study)	⊕◯◯◯[34] VERY LOW	RR 12.78 (0.69 to 236.44)
Tenofovir vs control	Maternal HBN DNA Suppression (at delivery)	2(observational studies)	⊕◯◯◯[34] VERY LOW	RR 45.4 (9.26 to 222.48)
	Maternal HBeAg seroconversion (at delivery)	1(observational studies)	⊕◯◯◯[34] VERY LOW	RR 6.33 (0.33 to 119.97)
	ALT normalization (before delivery)	45 (1 observational study)	⊕◯◯◯[34] VERY LOW	RR 1.3 (0.89 to 1.88)
	Cesarean section rate	78 (1 observational study)	⊕◯◯◯[4] VERY LOW	RR 1.72 (0.41 to 7.21)
	Postpartum hemorrhage	78 (1 observational study)	⊕◯◯◯[4] VERY LOW	RR 0.57 (0.15 to 2.19)
	Elevated Creatinine kinase rate	45 (1 observational study)	⊕◯◯◯[34] VERY LOW	RR 3.41 (0.15 to 79.47)
Telbivudine vs Lamivudine	Maternal HBV DNA suppression (at delivery)	387 (1 observational study)	⊕◯◯◯[3] VERY LOW	RR 1.83 (1.28 to 2.61)
	Maternal HBV DNA suppression	303	⊕◯◯◯[34]	RR 1.24

	(4 weeks postpartum)	(1 observational study)	VERY LOW	(0.78 to 1.97)
	Maternal HBeAg loss (at delivery)	310 (1 observational study)	⊕◯◯◯[34] VERY LOW	RR 1.05 (0.05 to 21.49)
	Maternal HBeAg seroconversion (at delivery)	310 (1 observational study)	⊕◯◯◯[34] VERY LOW	RR 0.63 (0.03 to 15.21)
	Cesarean section rate	387 (1 observational study)	⊕◯◯◯[4] VERY LOW	RR 1.05 (0.86 to 1.3)
	Elevated Creatinine kinase rate	318 (1 observational study)	⊕◯◯◯[34] VERY LOW	RR 1.91 (0.1 to 34.96)
Tenofovir vs Lamivudine	Cesarean section rate	111 (1 observational study)	⊕◯◯◯[4] VERY LOW	RR 0.76 (0.36 to 1.62)

Footnotes:

1. Increased risk of bias
2. Inconsistency
3. Indirectness
4. Imprecision